2024-03-18 10:00:07 ET
Summary
- Novo Nordisk's Wegovy represents a significant advancement in obesity treatment, demonstrating a more profound weight-loss effect compared to its predecessor, Saxenda.
- Eli Lilly's entry with Zepbound, targeting both GLP-1 and GIP, signifies a competitive market landscape, potentially outperforming Wegovy in efficacy.
- The race to redefine obesity treatment is heating up, with several other pharmaceutical companies developing GLP-1 agonists and exploring alternative targets.
The Evolution of Obesity Pharmacotherapy: From Phentermine to Wegovy
Read the full article on Seeking Alpha
For further details see:
Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront